Sorafenib delivered by cancer cell membrane remodels tumor microenvironment to enhances the immunotherapy of mitoxantrone in breast cancer

The negative regulation effect of tumor microenvironment (TME) greatly compromised the efficacy of various cancer treatments, especially cancer immunotherapy. As a result, it is generally recognized that remodeling of TME along with the treatment is a promising way to realize satisfactory cancer therapy. Here, in our study, a drug delivery system (DDS) composed cancer cell membrane (CCM) vehicle loaded mitoxantrone (Mit) and sorafenib (Sfn) was proposed with the aim to combine TME regulation and chemotherapy-induced immunotherapy in one platform. Our results confirmed that after treating with this DDS, the Mit induced immunogenic cell death (ICD) could be augmented by Sfn-based TME regulation to realize effective cancer immunotherapy. The Sfn was shown to downregulate of the regulatory T cells (Treg) level while activating the effector T cells of TME. The synergetic TME regulation along with cancer immunotherapy might be a promising way for advanced cancer treatment.